Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
RESEARCH TOOLSreports
Century Therapeutics (IPSC) Stock Price & Analysis
104 Followers
IPSC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $5.51
Previous Close$3.09
Volume112.75K
Average Volume (3M)218.01K
Market Cap
$200.62M
Enterprise Value$76.65M
Total Cash (Recent Filing)$169.50M
Total Debt (Recent Filing)$45.53M
Price to Earnings (P/E)-1.3
Beta1.27
Next Earnings
May 13, 2024EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding64,817,863
10 Day Avg. Volume155,078
30 Day Avg. Volume218,014
Standard Deviation0.30
R-Squared0.05
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.91
Price to Sales (P/S)384.43
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue30.81
Enterprise Value/Gross Profit14.74
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$15.33Price Target Upside396.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Century Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation progress of the Phase 1 CALiPSO-1 lupus trial showcases Century's dedication to advancing autoimmune disease treatments.
Financial HealthCentury's successful completion of a $60M private financing round reflects robust investor confidence in the company's innovative approach to cell therapy for autoimmune diseases.
Strategic AcquisitionsThe strategic acquisition of Clade Therapeutics positions Century to broaden its pipeline with cutting-edge induced pluripotent stem cell-derived therapies, potentially transforming treatment options in autoimmunity and oncology.
Bears Say
Financial PerformanceCentury reported a 2023 net loss per share, with expectations of continued net losses into 2024.
Market CompetitionCentury Therapeutics has traded disconnected from key CAR-NK competitors due to its relatively immature clinical state.
Market DynamicsThe late-line NHL market is shrinking as bi-specifics and other cell therapies progress into earlier lines of therapy.
---
Ownership Overview
59.14% Insiders
8.10% Mutual Funds
3.24% Other Institutional Investors
29.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $1.28 and its highest was $5.51 in the past 12 months.
What is Century Therapeutics’s market cap?
Currently, no data Available
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is May 13, 2024 which is in 17 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Mar 14, 2024. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.548 by -$0.112.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -$0.51.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 64,924,614 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.548. Following the earnings report the stock price went down -7.202%.
Which hedge fund is a major shareholder of Century Therapeutics?
Among the largest hedge funds holding Century Therapeutics’s share is Baker Bros Advisors LP. It holds Century Therapeutics’s shares valued at 3M.
---
Century Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (396.12% Upside)
$15.33 (396.12% Upside)
Blogger Sentiment
Neutral
IPSC Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 351.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.4%
Last 30 Days ▼ 17.0%
Last 30 Days ▼ 17.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.90%
12-Months-Change
Fundamentals
Return on Equity
-56.07%
Trailing 12-Months
Asset Growth
-25.87%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
IPSC Stock 12 Months Forecast
Average Price Target
$15.33
▲(396.12% Upside)
Technical Analysis
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-15.61%
reiterated a buy rating 14 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -15.61% per trade.
---